Epibatidine application in vitro blocks retinal waves without silencing all retinal ganglion cell action potentials in developing retina of the mouse and ferret

体外应用地巴替丁可阻断小鼠和雪貂正在发育的视网膜中的视网膜波,但不会抑制所有视网膜神经节细胞动作电位

阅读:13
作者:Chao Sun, Colenso M Speer, Guo-Yong Wang, Barbara Chapman, Leo M Chalupa

Abstract

Epibatidine (EPI), a potent cholinergic agonist, disrupts acetylcholine-dependent spontaneous retinal activity. Early patch-clamp recordings in juvenile ferrets suggested that EPI blocks all retinal ganglion cell (RGC) action potentials when applied to the retina. In contrast, recent experiments on the developing mouse that relied on multielectrode array (MEA) recordings reported that EPI application decorrelates the activity of neighboring RGCs and eliminates retinal waves while preserving the spiking activity of many neurons. The different techniques used in previous studies raise the question of whether EPI has different effects on RGC activity in mouse compared with that in ferret. A resolution of this issue is essential for interpreting the results of developmental studies that relied on EPI to manipulate retinal activity. Our goal was to compare the effects of EPI on the spontaneous discharges of RGCs in mouse and ferret using 60-electrode MEA as well as patch-clamp recordings during the developmental stage when retinal waves are driven by acetylcholine in both species. We found that in both mouse and ferret EPI decorrelates RGC activity and eliminates retinal waves. However, EPI does not block all spontaneous activity in either species. Instead, our whole cell recordings reveal that EPI silences more than half of all RGCs while significantly increasing the activity of the remainder. These results have important implications for interpreting the results of previous studies that relied on this cholinergic agonist to perturb retinal activity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。